Trials / Approved For Marketing
Approved For MarketingNCT03089658
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity. |
Timeline
- First posted
- 2017-03-24
- Last updated
- 2019-10-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03089658. Inclusion in this directory is not an endorsement.